BioCentury | Mar 21, 2020
Product Development

View from Italy: COVID-19 stalls early-stage companies, could create bargains for international VCs

...one case of a patient refusing treatment to avoid exposure at the hospital. Italian biotech Erydel S.p.A....
...ataxia telangiectasia, and is the largest trial ever conducted in the indication, he said. While Erydel’s...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...agency. Xenikos B.V. hired Stanley Musial as CFO and CBO. Musial served as CFO of EryDel S.p.A....
BioCentury | May 18, 2015
Financial News

EryDel financial update

...EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Date announced: 2015-05-11 Note: EryDel raised EUR14.5...
BioCentury | Oct 20, 2014
Company News

EryDel management update

EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Hired: Rene Goedkoop as CMO, a newly created position, formerly CMO of Sensimed AG WIR Staff...
BioCentury | Mar 3, 2014
Clinical News

EryDex: Additional Phase II data

...months by 1.3 points (p<0.0001). Data were published in the Orphanet Journal of Rare Disease. EryDel...
...recessive disorder. EryDex is also in Phase II testing to treat Duchenne muscular dystrophy (DMD). EryDel S.p.A....
BioCentury | Aug 5, 2013
Company News

EryDel board of directors update

EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Appointed: Lorenzo Tallargio, CEO of Genextra S.p.A. WIR Staff...
BioCentury | Aug 5, 2013
Financial News

EryDel completes venture financing

EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Date completed: 7/31/13 Type: Venture financing Raised: €15 million ($19.9 million) Investors: Genextra; Innogest; Focus Gestioni WIR Staff Neurology...
BioCentury | Aug 1, 2013
Financial News

EryDel raises EUR 15 million in B round

...investors Innogest and Focus Gestioni. Genextra's CEO Lorenzo Tallarigo will join EryDel's board. In 1H14, EryDel...
BioCentury | Jun 11, 2012
Company News

EryDel management update

EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Hired: Luca Benatti as CEO and a director, formerly CEO of Newron Pharmaceuticals S.p.A. WIR Staff Neurology...
BioCentury | Mar 5, 2012
Clinical News

EryDex: Phase II data

...study entry according to the company. No adverse events were considered related to EryDex treatment. EryDel...
...recessive disorder. EryDex is also in Phase II testing to treat Duchenne muscular dystrophy (DMD). EryDel S.p.A....
Items per page:
1 - 10 of 11
BioCentury | Mar 21, 2020
Product Development

View from Italy: COVID-19 stalls early-stage companies, could create bargains for international VCs

...one case of a patient refusing treatment to avoid exposure at the hospital. Italian biotech Erydel S.p.A....
...ataxia telangiectasia, and is the largest trial ever conducted in the indication, he said. While Erydel’s...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...agency. Xenikos B.V. hired Stanley Musial as CFO and CBO. Musial served as CFO of EryDel S.p.A....
BioCentury | May 18, 2015
Financial News

EryDel financial update

...EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Date announced: 2015-05-11 Note: EryDel raised EUR14.5...
BioCentury | Oct 20, 2014
Company News

EryDel management update

EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Hired: Rene Goedkoop as CMO, a newly created position, formerly CMO of Sensimed AG WIR Staff...
BioCentury | Mar 3, 2014
Clinical News

EryDex: Additional Phase II data

...months by 1.3 points (p<0.0001). Data were published in the Orphanet Journal of Rare Disease. EryDel...
...recessive disorder. EryDex is also in Phase II testing to treat Duchenne muscular dystrophy (DMD). EryDel S.p.A....
BioCentury | Aug 5, 2013
Company News

EryDel board of directors update

EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Appointed: Lorenzo Tallargio, CEO of Genextra S.p.A. WIR Staff...
BioCentury | Aug 5, 2013
Financial News

EryDel completes venture financing

EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Date completed: 7/31/13 Type: Venture financing Raised: €15 million ($19.9 million) Investors: Genextra; Innogest; Focus Gestioni WIR Staff Neurology...
BioCentury | Aug 1, 2013
Financial News

EryDel raises EUR 15 million in B round

...investors Innogest and Focus Gestioni. Genextra's CEO Lorenzo Tallarigo will join EryDel's board. In 1H14, EryDel...
BioCentury | Jun 11, 2012
Company News

EryDel management update

EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Hired: Luca Benatti as CEO and a director, formerly CEO of Newron Pharmaceuticals S.p.A. WIR Staff Neurology...
BioCentury | Mar 5, 2012
Clinical News

EryDex: Phase II data

...study entry according to the company. No adverse events were considered related to EryDex treatment. EryDel...
...recessive disorder. EryDex is also in Phase II testing to treat Duchenne muscular dystrophy (DMD). EryDel S.p.A....
Items per page:
1 - 10 of 11